Lipid formulations of amphotericin B: Clinical efficacy and toxicities

Clinical Infectious Diseases

Volumn 27, Issue 3, 1998, Pages 603-618

  Wong Beringer, Annie ^a   Jacobs, Richard A ^b   Guglielmo, B Joseph ^b  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE;

DRUG COST; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; INFECTION RISK; LIPID ANALYSIS; LIPID METABOLISM; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TREATMENT INDICATION;

EID: 0031686559     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514704     Document Type: Review

References (5)

1. Lopez-Berestein G, Hopfer RL, Mehta R, Mehta K, Hersh EM, Juliano RL. Liposome-encapsulated amphotericin B for the treatment of disseminated candidiasis in neutropenic mice. J Infect Dis 1984;150:278-83.
2. Bangham AD. Liposomes: realizing their promise. Hosp Pract Off Ed 1992;27:51-6, 61-2.
3. Ostro MJ, Cullus PR. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm 1989;46:1576-87.
4. Lopez-Berestein G. Liposomes as carriers of antimicrobial agents. Antimicrob Agents Chemother 1987;31:675-8.
5. Lopez-Berestein G, Fainstein V, Hopfer R, et al. Liposomal amphotericin B for the treatment of fungal infections in patients with cancer: a preliminary report. J Infect Dis 1985;151:704-10.